Business
PacBio To Begin Commercial Shipment of Revio Systems
Broad Commercialization and Scale-Up of Revio Enables Researchers with 15 Times More HiFi Data and High-Quality Human Genomes for Under $1,000 MENLO PARK,
About this update from Pacific Biosciences Of California, Inc.
[{"type":"text","content":"Broad Commercialization and Scale-Up of Revio Enables Researchers with 15 Times More HiFi Data and High-Quality Human Genomes for Under $1,000\nMENLO PARK, Calif., March 7, 2023 /PRNewswire/ -- PacBio (NASDAQ: PACB), a leading developer of high-quality, highly accurate sequencing solutions, today announced the first customer shipments of Revio long-read sequencing systems will commence on March 8, 2023. As previously announced, the Revio system features significant advances in SMRT Cell design, compute, and system architecture. Together, this enables a dramatic increase in throughput and lower sequencing costs with the trusted power of HiFi chemistry, which offers exceptional accuracy and direct methylation detection.\n\n \n \n \n \n \n \n\n \n\"Revio is a remarkable product, and I am excited to announce the commencement of broad commercial shipments. This is an important step in our mission to enable the promise of genomics to better human health and it is rewarding to see our team successfully execute on our aggressive product development timeline,\" said Christian Henry, President and Chief Executive Officer of PacBio. \"The Revio system will empower our customers to leverage the power of HiFi sequencing at scale and I believe the system will enable a significant paradigm shift in our understanding of biology.\" \nWith the Revio system, researchers will be able to scale their interrogation of the full genome: from telomere-to-telomere with phasing information, small variants, structural variants, and epigenetic profiles all in the same run. This will allow further exploration of biology and offers the potential to better understand the role of genetics in health and disease.\nAmong the first customers receiving Revio systems are many who have deep roots in the Human Genome Project: Baylor College of Medicine, the Broad Institute of MIT and Harvard (Broad), Wellcome Sanger Institute, and Washington University in St. Louis. Broad is one of many customers to purchase multiple systems, ordering ten Revio systems to scale long-read sequencing for population sequencing initiatives. The ten Revio systems at Broad will have the same sequencing capacity as 150 Sequel IIe systems.\n\"With the increased capacity now available, the Broad is looking to scale up significantly and complete several thousand long-read sequencing samples,\" sa...